Dupixent® is the commercial brand name of Dupilumab Injection, a fully human monoclonal antibody against IL-4Rα developed by Sanofi. It blocks IL-4 and IL-13 signaling to suppress type 2 inflammatory responses. Main IndicationsModerate-to-severe atopic dermatitis, uncontrolled asthma, chronic rhinosinusitis with…
Evrysdi® is the commercial brand name of Risdiplam powder for oral solution, an orally administered splicing modifier developed by Roche. It modulates SMN2 gene splicing to elevate functional SMN protein level for spinal muscular atrophy treatment. Main IndicationsTreatment of spinal…
TEVIMBRA® is the overseas commercial brand name. Its generic English name is Tislelizumab Injection, a humanized anti-PD-1 IgG4 monoclonal antibody independently developed by BeiGene. It blocks PD-1/PD-L1 binding to reactivate body’s own anti-tumor immune T cells, with modified Fc segment…
Akeega® is the commercial brand name of Niraparib Tosylate and Abiraterone Acetate Tablets, an oral fixed-dose combination drug developed by Johnson & Johnson. It combines PARP inhibitor niraparib and androgen synthesis inhibitor abiraterone to block dual pathogenic pathways of advanced…
Meiyouheng® is the commercial brand name of Becotatug Vedotin for Injection, an antibody-drug conjugate developed by Lepu Biopharma. It targets Nectin-4 antigen on nasopharyngeal carcinoma cells and delivers cytotoxic payload to induce tumor cell death. Main IndicationsTreatment of adult patients…
Rhapsido® is the commercial brand name of Remibrutinib Tablets, an orally selective BTK inhibitor developed by BeiGene. It inhibits Bruton’s tyrosine kinase to block abnormal B-cell activation and reduce inflammatory response. Main IndicationsTreatment of adult patients with chronic spontaneous urticaria…
Myqorzo® is the commercial brand name of Aficamten Tablets, an orally selective cardiac myosin inhibitor developed by Cytokinetics and marketed by Sanofi. It reduces excessive myocardial contraction by inhibiting cardiac myosin ATPase activity, relieving cardiac hypertrophy of obstructive hypertrophic cardiomyopathy.…
Inlyta® is the commercial brand name of Axitinib Tablets, an orally selective multi-target VEGFR tyrosine kinase inhibitor developed by Pfizer. It suppresses vascular endothelial growth factor receptor to block tumor angiogenesis and inhibit renal carcinoma proliferation. Main IndicationsTreatment of advanced…
Jakavi® is the commercial brand name of Ruxolitinib Phosphate Tablets, an orally active selective JAK1/JAK2 inhibitor developed by Novartis. It blocks abnormal JAK-STAT signaling pathway to relieve splenomegaly and disease-related symptoms caused by myeloproliferative neoplasms. Main IndicationsTreatment of intermediate or…
Nerlynx® is the commercial brand name of Neratinib Maleate Tablets, an orally active irreversible pan-HER tyrosine kinase inhibitor developed by Puma Biotechnology. It irreversibly inhibits EGFR, HER2 and HER4 to block downstream oncogenic signaling and restrain tumor cell proliferation. Main…